- Home
- ZENV vs CASI Comparison
ZENV vs CASI Comparison
Compare ZENV & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- CASI
- Stock Information
- Founded
- ZENV 2005
- CASI 1991
- Country
- ZENV Brazil
- CASI China
- Employees
- ZENV N/A
- CASI N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- CASI Health Care
- Exchange
- ZENV Nasdaq
- CASI Nasdaq
- Market Cap
- ZENV 63.3M
- CASI 58.8M
- IPO Year
- ZENV 2021
- CASI 1996
- Fundamental
- Price
- ZENV $1.62
- CASI $2.78
- Analyst Decision
- ZENV
- CASI Strong Buy
- Analyst Count
- ZENV 0
- CASI 1
- Target Price
- ZENV N/A
- CASI $6.00
- AVG Volume (30 Days)
- ZENV 73.5K
- CASI 55.0K
- Earning Date
- ZENV 11-18-2024
- CASI 11-15-2024
- Dividend Yield
- ZENV N/A
- CASI N/A
- EPS Growth
- ZENV N/A
- CASI N/A
- EPS
- ZENV N/A
- CASI N/A
- Revenue
- ZENV $173,594,726.00
- CASI $22,055,000.00
- Revenue This Year
- ZENV $25.56
- CASI N/A
- Revenue Next Year
- ZENV $6.02
- CASI $134.79
- P/E Ratio
- ZENV N/A
- CASI N/A
- Revenue Growth
- ZENV 23.49
- CASI N/A
- 52 Week Low
- ZENV $1.00
- CASI $2.05
- 52 Week High
- ZENV $3.88
- CASI $8.19
- Technical
- Relative Strength Index (RSI)
- ZENV 54.93
- CASI 29.28
- Support Level
- ZENV $1.61
- CASI $2.50
- Resistance Level
- ZENV $1.78
- CASI $3.47
- Average True Range (ATR)
- ZENV 0.12
- CASI 0.47
- MACD
- ZENV -0.00
- CASI -0.02
- Stochastic Oscillator
- ZENV 48.48
- CASI 10.32
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.